IRIDEX
IRIDEX Corporation develops and manufactures proprietary MicroPulse laser systems for ophthalmology, serving ophthalmologists and retina/glaucoma specialists in hospitals, ASCs, and practices across 60+ countries. It generates revenue from capital laser consoles and recurring single-use consumables.
- Company typePublic
- Founded1989
- HeadquartersMountain View, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What IRIDEX does
IRIDEX Corporation, founded in 1989 and listed on NASDAQ under ticker IRIX, develops and manufactures laser-based medical systems for ophthalmic applications, serving ophthalmologists, retina specialists, glaucoma specialists, and veterinary ophthalmologists across hospitals, ambulatory surgery centers, and office-based practices. Its product portfolio is anchored by the proprietary MicroPulse tissue-sparing laser technology, protected by a European patent granted February 2024, and centers on two therapeutic franchises: Glaucoma (Cyclo G6 810nm infrared laser, MicroPulse P3 device, G-Probe, G-Probe Illuminate, MLT lens) and Retina (IQ 532, IQ 577, OcuLight, and the PASCAL platform with Synthesis, TwinStar, and LIO variants), complemented by EndoProbe handpieces and TxCell scanning delivery systems. The MicroPulse platform enables repeatable, fovea-friendly treatments that reduce collateral tissue damage versus continuous-wave lasers, with a five-year clinical study and independent Maastricht retreatment data supporting efficacy claims.
The company generates revenue through a mix of one-time capital equipment sales of laser consoles and a recurring stream of single-use consumables such as G-Probe devices (CPT code 66710, reimbursed at $453 in physician office and $836 in ASC facility settings), plus service and support. IRIDEX distributes through a U.S. direct field sales force, a wholly-owned European subsidiary (Iridex Europe GmbH in Mannheim), over 100 international distributors covering 60+ countries, and the EyeProGPO group purchasing organization partnership that reaches 1,800+ member practices. Under CEO Patrick Mercer (appointed October 2024), IRIDEX achieved positive adjusted EBITDA in Q4 2025 on 16% quarterly revenue growth and an 8% full-year revenue gain to $52.7M, while restructuring operations including a 2026 headquarters relocation from Mountain View to San Jose and the transition to third-party manufacturing to capture $0.4M-$0.6M in annual cost savings.
IRIDEX firmographics
Firmographics- Name
- IRIDEX
- Legal name
- Iridex Corporation
- Website
- https://iridex.com
- Company type
- Public
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- IRIDEX Corporation develops and manufactures proprietary MicroPulse laser systems for ophthalmology, serving ophthalmologists and retina/glaucoma specialists in hospitals, ASCs, and practices across 60+ countries. It generates revenue from capital laser consoles and recurring single-use consumables.
- Ownership category
- akta.pro rank
IRIDEX industry classification
Industry- Product category
- Ophthalmic Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty) (HLAHAJAI)
- akta.pro secondary industry
- Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades) (HLAHAJAJ)
Keywords
Where IRIDEX is headquartered
LocationHeadquarters
- HQ city
- Mountain View
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
IRIDEX business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Laser Systems (Capital Equipment): Sale of laser console systems including Cyclo G6, IQ 532, IQ 577, OcuLight, and PASCAL platforms. These are capital equipment purchases by hospitals, ASCs, and physician practices.
- Consumables and Delivery Devices: Recurring revenue from single-use consumables including G-Probe devices (sold in boxes of 6), glaucoma probes, laser probes, and other disposable delivery devices used during procedures.
- Service and Support: Technical and customer support services for installed base of laser systems.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | G-Probe single-use delivery device |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
IRIDEX product offering
Product offeringCore offering
IRIDEX develops, manufactures, and markets laser-based medical systems and single-use delivery devices used by ophthalmologists, retina specialists, and glaucoma specialists to treat retinal diseases (including diabetic macular edema, age-related macular degeneration, and central serous chorioretinopathy) and glaucoma. Its core platforms are the Cyclo G6, IQ 532, IQ 577, OcuLight, and PASCAL laser systems, along with proprietary MicroPulse tissue-sparing technology and consumable delivery devices such as the G-Probe, G-Probe Illuminate, and MicroPulse P3. Revenue is generated through capital equipment sales to hospitals, ambulatory surgery centers, and physician offices, recurring consumable purchases, and service and support contracts.
Product overview
IRIDEX is a medical laser systems company developing and manufacturing laser-based products for ophthalmology treatments. The product portfolio centers on two therapeutic areas: Glaucoma and Retina. Core glaucoma products include the Cyclo G6 laser system (810 nm infrared), MicroPulse P3 device, G-Probe and G-Probe Illuminate for transscleral cyclophotocoagulation, and MLT lens for laser trabeculoplasty. Retina products include the IQ 532 (green, 532 nm) and IQ 577 (yellow, 577 nm) laser systems, OcuLight lasers, and the PASCAL laser platform with Synthesis, TwinStar, and LIO variants. The proprietary MicroPulse technology platform enables tissue-sparing treatments by delivering laser energy in repetitive pulses. Products are sold through direct sales and distributor networks in over 60 countries. Accessories include EndoProbe handpieces, TxCell scanning delivery system, LIO devices, and veterinary/ENT products.
Differentiator
Problem solved
Functional benefit
Brands
- PASCAL: PASCAL (Patterned Scanning Laser) laser platform for retina treatments, including PASCAL Synthesis and PASCAL TwinStar systems
- MicroPulse
- Cyclo G6
- IQ Lasers
- EndoProbe
- TxCell
- G-Probe
- OcuLight
Products and services
- Cyclo G6 Laser System 810 nm infrared laser system for glaucoma treatment that can operate in both MicroPulse mode and continuous-wave mode for transscleral cyclophotocoagulation (TSCPC). Available in more than 60 countries.
- IQ 532 Laser 532 nm green wavelength laser system for retinal treatments, delivering high power up to 2500 mW with pulse durations from 100 to 3000 ms, available with MicroPulse technology for fovea-friendly treatments.
- IQ 577 Laser 577 nm yellow wavelength laser preferred by retina surgeons for peak absorption in oxygenated hemoglobin tissues, available with MicroPulse technology for fovea-friendly retinal treatments.
- OcuLight Laser System Diode laser systems for ophthalmic applications including SL, SLx, GL, GLx, and TX variants for retinal photocoagulation treatments.
- PASCAL Laser Platform Gold standard patterned scanning laser platform for retina treatments featuring a patented 4-fiber design for high-volume efficiency; now available with MicroPulse technology integration. Includes PASCAL Synthesis, PASCAL TwinStar, and PASCAL LIO variants.
- G-Probe Delivery Device Single-use delivery device for continuous-wave transscleral cyclophotocoagulation (CW-TSCPC) to lower intraocular pressure by selective ablation of ciliary processes; validated for single use only with 3-year shelf life and sold in boxes of 6 (part number 15980).
- G-Probe Illuminate Enhanced G-Probe variant with integrated illumination for improved visualization during transscleral cyclophotocoagulation procedures.
- MicroPulse P3 Device Delivery device enabling MicroPulse transscleral laser treatment using the Cyclo G6 laser system for glaucoma management with tissue-sparing benefits.
- MicroPulse Laser Trabeculoplasty (MLT) Lens Specialized contact lens for MicroPulse laser trabeculoplasty procedures in glaucoma treatment.
- EndoProbe Handpieces Family of laser delivery handpieces for vitreoretinal surgery, providing precise energy delivery with optional MicroPulse compatibility for tissue-sparing treatments in operating room settings.
- TxCell Scanning Laser Delivery System Multi-spot pattern scanning system compatible with IQ 532 and IQ 577 lasers, enabling efficient retinal photocoagulation with confluent patterns for tissue-sparing MicroPulse protocols.
- LIO (Laser Indirect Ophthalmoscope) Delivery device for indirect laser delivery through the pupil for retinal treatments, compatible with various Iridex laser systems.
- Veterinary Laser Products Laser systems and accessories designed for veterinary ophthalmology applications for treating animal eye conditions.
- ENT Laser Products Laser systems designed for ear, nose, and throat surgical applications.
- Vexio Cart Mobile cart system for transporting and positioning Iridex laser systems in clinical settings.
Quantifiable outcome
- Intraocular pressure reductions of 25-35% in glaucoma patients using MicroPulse transscleral laser treatment
- +3 more outcomes
Companies that use IRIDEX
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
IRIDEX technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
IRIDEX partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- EyeProGPOcorePartnership with ophthalmology-focused group purchasing organization to provide preferred pricing on IRIDEX retina laser technology to EyeProGPO's 1,800+ member practices, ambulatory surgery centers, and hospitals across the United States. The agreement expands an existing relationship that already included IRIDEX's Cyclo G6 laser and glaucoma probes by adding the PASCAL laser platform, IQ 532 and IQ 577 lasers, and OcuLight TX laser. CEO Patrick Mercer stated the on-contract status reinforces technology credibility and streamlines the sales process while delivering clinical and economic value to retina specialists.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
IRIDEX competitors and assessment
Company assessmentMarket position
Strengths4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
IRIDEX social profiles
Digital presenceIRIDEX financial estimates
Financial estimateRevenue estimate
Valuation estimate
IRIDEX leadership team
Management profileNumber of profiles
Profiles3 records
IRIDEX subsidiaries and ownership
Company hierarchySubsidiaries1 record
IRIDEX funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IRIDEX M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IRIDEX
What does IRIDEX do?
IRIDEX develops, manufactures, and markets laser-based medical systems and single-use delivery devices used by ophthalmologists, retina specialists, and glaucoma specialists to treat retinal diseases (including diabetic macular edema, age-related macular degeneration, and central serous chorioretinopathy) and glaucoma. Its core platforms are the Cyclo G6, IQ 532, IQ 577, OcuLight, and PASCAL laser systems, along with proprietary MicroPulse tissue-sparing technology and consumable delivery devices such as the G-Probe, G-Probe Illuminate, and MicroPulse P3. Revenue is generated through capital equipment sales to hospitals, ambulatory surgery centers, and physician offices, recurring consumable purchases, and service and support contracts.
Is IRIDEX a public or private company?
IRIDEX is a public company. It is classified as public and is currently operating.
When was IRIDEX founded?
IRIDEX was founded in 1989. It employs 101 to 250 people.
Where is IRIDEX based?
IRIDEX is headquartered in Mountain View, United States, in the North America region.
How does IRIDEX make money?
Three revenue lines are on record. Laser Systems (Capital Equipment) is the primary driver. The others are consumables and Delivery Devices and service and Support.
Does IRIDEX have an API?
No public API is recorded for IRIDEX.
What industry is IRIDEX in?
IRIDEX's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAI, Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty), with a secondary code of HLAHAJAJ, Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades). Its NAICS code is 339113 and its SIC code is 3841.